Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ligand Earns Pfizer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ligand Earns Pfizer Milestone

Ligand Pharmaceuticals and Pfizer have sublicensed Tanaproget, also known as NSP-989, to a multi-national pharmaceutical company.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ligand Pharmaceuticals and Pfizer have sublicensed Tanaproget, also known as NSP-989, to a multi-national pharmaceutical company. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer, as well as royalties on sales.

Tanaproget is a tissue-selective, non-steroidal contraceptive progesterone receptor agonist that has the potential for an improved side effect profile over current steroid-containing contraceptives. The sublicensee is now responsible for the worldwide development, registration and commercialization of Tanaproget.

“We are pleased with Pfizer’s decision to enable further progression of Tanaproget through this sublicense agreement. Tanaproget is an example of the significant progress made in the field of women’s health, providing an additional oral contraceptive option for women using both prescription and non-prescription methods of contraception,” said John L. Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Our collaborative relationship with Pfizer continues to be very productive and this sublicense adds another promising program to Ligand’s large portfolio of assets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters